You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Novartis AG buying Cambridge cancer drug firm

CoStim purchase boosts push into immunotherapy

The Swiss drug giant Novartis AG, moving to establish itself as a top player in the hot field of cancer treatment known as immunotherapy, on Monday said it had snapped up two-year-old CoStim Pharmaceuticals Inc., a venture-backed Cambridge biotech using research from Boston academic labs.

CoStim, bankrolled by local venture firms MPM Capital and Atlas Ventures as well as Partners Innovation Fund, is developing a pipeline of drugs that stimulate a patient’s immune system to fight cancer. CoStim will be rolled into Novartis’s Cambridge-based immunotherapies research team, which will start with 20 to 30 people but is likely to expand.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week